The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Creative Biogene
-
- Employees
-
Key takeaway
Creative Biogene is dedicated to advancing research in life sciences, including areas like preclinical drug discovery. Their focus on developing unique technologies and high-quality products positions them as a key player in supporting investigations related to oncolytic viruses.
Highlighted product
Product
Oncolytic Virus - Creative Biogene
Humane Genomics
New York, United States
B
1-10 Employees
2019
Key takeaway
The company is focused on revolutionizing cancer treatment through the development of oncolytic viruses that selectively target and destroy cancer cells. Their advanced platform accelerates the design and testing of these therapies, ensuring high selectivity and efficiency compared to traditional treatments.
Highlighted product
Core business
Home - Humane Genomics
We create oncolytic viruses with unprecedented selectivity and efficiency. Using our platform we engineer therapeutics with unprecedented selectivity and efficiency over traditional treatments. Artificial virus platform Our “digital first” approach to designing therapeutics ensures safety and efficacy in targeted cancer treatment. We are building a library of verified and reusable components Viruses are designed on a computer using our library of verified genetic sequences and virus features. Code is synthesized into sequence perfect fragments. This reliability cuts steps and time... Read More Read More
CanVirex
Basel, Switzerland
A
1-10 Employees
2017
Key takeaway
CanVirex is focused on developing innovative cancer treatments, specifically utilizing a promising oncolytic measles virus-vectored platform for cancer immunotherapy. Their collaboration with Heidelberg University Hospital enhances the research and clinical development of these advanced therapeutics.
Highlighted product
Core business
CanVirex – Targeted oncolytic immunomodulation breaking tumor resistance
Targeted oncolytic immunomodulation breaking tumor resistance
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
NeoVirTech
Toulouse, France
A
1-10 Employees
2014
Key takeaway
NeoVirTech is focused on advancing virology research through innovative imaging techniques, particularly highlighting their ANCHOR™ technology, which enables real-time visualization of viral infections. This capability is crucial for the development of oncolytic therapies that use viruses to target and destroy tumor cells, offering new hope in cancer treatment.
Highlighted product
Product
Oncology - NeoVirTech
Virus as a cancer therapy Oncology Oncolytics vectors Conventional cancer treatments have limited effectiveness in many cases. Oncolytic therapy, based on the use of armed viruses directed against tumor cells, offers new perspectives in the fight against this global scourge. In this context, our ANCHOR™ system allows the visualization of the early stages of infection […]
WuXi Discovery Services
Panyu District, China
D
10001+ Employees
2000
Key takeaway
WuXi Biology provides a comprehensive platform of oncolytic virus-related services, including lysis activity, cytokine assessment, efficacy testing, and safety assays. Their expertise in oncology and advanced discovery technologies supports the rapid advancement of oncolytic virus programs from target discovery to preclinical selection.
Highlighted product
Product
Oncolytic Viruses - WuXi Biology
Offering a comprehensive platform of oncolytic virus-related services, including lysis activity, cytokine assessment, efficacy testing & safety assays.
DNAtriX
Houston, United States
B
11-50 Employees
2005
Key takeaway
DNAtrix is focused on developing oncolytic immunotherapies, particularly DNX-2401, which is designed to selectively infect and kill cancer cells while stimulating a robust anti-tumor immune response. This innovative approach targets hard-to-treat cancers, including aggressive brain tumors like glioblastoma and DIPG.
Highlighted product
Product
DNX-2401 (Tasadenoturev) | DNAtrix
Thats Nice
New York, United States
B
51-100 Employees
1995
Key takeaway
Vibalogics specializes in oncolytic viruses, highlighting their expertise in this innovative area of cancer treatment.
Highlighted product
Core business
Vibalogics, Oncolytic Viruses
Vibalogics, Oncolytic Viruses
ImmVirX
Newcastle, Australia
A
11-50 Employees
2019
Key takeaway
ImmVirX is developing a novel oncolytic immunotherapy that utilizes proprietary RNA viruses to selectively target and kill cancer cells while enhancing immune responses. Their approach aims to improve the efficacy of existing cancer treatments, particularly for difficult-to-treat cancers.
Highlighted product
Core business
ImmVirX - Receptor Targeted Oncolytic Viruses
ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.
Vyriad
Rochester, United States
B
11-50 Employees
2016
Key takeaway
Vyriad is focused on developing innovative oncolytic virus therapies that specifically target and destroy cancer cells while also enhancing the immune response to prevent recurrence. Their proprietary technology, particularly using Vesicular Stomatitis Virus (VSV) and measles, shows great promise in transforming cancer treatment and improving patient outcomes.
Highlighted product
Core business
About Vyriad - Vyriad
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic, Imanis Life Sciences and the University of Miami. The Company has exclusive licenses to technologies ...
Oncolytics Biotech
Calgary, Canada
A
11-50 Employees
1988
Key takeaway
Oncolytics is focused on improving the lives of cancer patients through innovative treatments like pelareorep, a unique immunotherapy that activates the immune system to enhance its antitumor effects. This approach distinguishes pelareorep from traditional immunotherapies by allowing systemic delivery, potentially benefiting a wide range of cancer indications.
Highlighted product
Core business
Oncolytics Biotech, Inc. (ONCY)
Technologies which have been searched by others and may be interesting for you:
Oncolytic viruses are a class of viruses that selectively infect and destroy cancer cells while sparing normal cells. These viruses can replicate within tumor cells, leading to their lysis or death. Additionally, they can stimulate the immune system to recognize and attack the cancer more effectively. This dual action makes oncolytic viruses a promising approach in cancer therapy, combining direct tumor destruction with potential immunotherapy benefits. Researchers are actively investigating various types of oncolytic viruses, including genetically modified strains, to enhance their efficacy and safety in treating different cancer types.
Oncolytic viruses are designed to selectively infect and kill cancer cells while sparing healthy tissue. These viruses exploit the unique characteristics of cancer cells, which often have compromised antiviral defenses. Once inside the cancerous cells, the virus replicates, leading to cell lysis and subsequent release of new viral particles. This process not only destroys the tumor cells directly but also triggers an immune response against the cancer. In addition to direct cytotoxicity, oncolytic viruses can stimulate the immune system to recognize and attack tumors. They can enhance the presentation of tumor antigens, making it easier for immune cells to identify and eliminate cancer cells throughout the body. As a result, oncolytic virus therapy represents a promising avenue for targeted cancer treatment, with the potential to improve outcomes for patients.
1. Targeted Cancer Treatment
Oncolytic viruses selectively infect and kill cancer cells while sparing healthy cells. This specificity minimizes damage to surrounding tissues and reduces side effects commonly associated with conventional therapies such as chemotherapy and radiation.
2. Immune Response Activation
The use of oncolytic viruses can stimulate a robust immune response against tumors. As these viruses replicate within cancer cells, they can induce the release of tumor antigens, helping to educate the immune system to recognize and attack not only the infected cells but also neighboring cancerous cells.
3. Potential for Combination Therapy
Oncolytic virus therapy can be effectively combined with other treatments, including immune checkpoint inhibitors and targeted therapies. This synergistic approach can enhance overall treatment efficacy, leading to improved patient outcomes in various types of cancer.
4. Versatile Application
These viruses can be engineered to target specific types of cancer, making them versatile tools in cancer therapy. Their adaptability allows researchers to modify the viral genome to enhance their effectiveness against different tumor types or to improve their safety profiles.
Oncolytic virus therapy, while promising in cancer treatment, carries certain risks that must be considered. Patients may experience immune responses to the virus, which can lead to flu-like symptoms, inflammation, or allergic reactions. Additionally, there is a potential for tumor lysis syndrome, a condition that can occur when cancer cells are rapidly destroyed, releasing their contents into the bloodstream and potentially causing kidney damage or other complications. Another concern is the risk of viral spread, as the oncolytic virus may inadvertently infect healthy cells or tissues, leading to unintended effects. Monitoring and managing these risks is crucial for the safe application of this innovative therapy, ensuring that the benefits outweigh the potential adverse effects.
Oncolytic viruses are engineered to selectively infect and destroy cancer cells while sparing healthy tissue. These viruses have shown promise in targeting various types of cancers, including melanoma, glioblastoma, and pancreatic cancer. Additionally, they can also be effective against breast, ovarian, and prostate cancers. By harnessing the body's immune response, oncolytic viruses not only attack tumors directly but also stimulate an immune reaction that can further help in combating cancer spread.
Some interesting numbers and facts about your company results for Oncolytic Virus
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 5066 |
| Amount of suitable service providers | 3240 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1988 |
| Youngest suiting company | 2019 |
20%
40%
60%
80%
Some interesting questions that has been asked about the results you have just received for Oncolytic Virus
What are related technologies to Oncolytic Virus?
Based on our calculations related technologies to Oncolytic Virus are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Oncolytic Virus?
The most represented industries which are working in Oncolytic Virus are Biotechnology, Other, IT, Software and Services, Medical, Pharmaceuticals
How does ensun find these Oncolytic Virus Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
